Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
Date:1/28/2009

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2008 financial results.

    U.S. / Canada Dial-in Number:  866.700.6293
    International Dial-in Number:  617.213.8835
    Participant Code: 35749059
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 73992450

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell di
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Piper Jaffray Healthcare Conference
2. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
3. BioMarin to Present at the Credit Suisse Healthcare Conference
4. BioMarin Announces Third Quarter 2008 Financial Results
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
7. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
8. BioMarin to Present at the Citi Biotech Day
9. BioMarin Announces Roll-Out of National PKU Registry
10. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Collins Stewart Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Kerr Corporation, a ... video and additional how-to information about dual arch impressions on ... with Dual Arch Impressions,” the blog entry serves up a ... and houses a step-by-step demonstration by Dr. David Little as ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... ... Earned Value Management can improve control over clinical development costs, payments, and accruals and ... , ... June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical trial ...
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that the FDA has granted 510(k) ... the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone ... a new era of insertion devices for the company ...
... June 11 New data from Phase 3 ... (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* ... provide coverage against the 13 most prevalent serotypes associated with ... children younger than five worldwide. , , ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6
(Date:7/10/2014)... 10, 2014) Consuming a whole fresh avocado with ... enhanced provitamin A carotenoid (alpha- and beta-carotene) absorption and ... vitamin A, according to new research (1) published ... , Vitamin A is involved in reproductive health ... and vision; and has antioxidant properties. Provitamin A carotenoids, ...
(Date:7/9/2014)... diseases can occur simultaneously in distinct sites in ... effective for one disorder may exacerbate the other. ... which alleviates joint disease but can worsen periodontal ... of The American Journal of Pathology ... anti-arthritic drugs, specifically DTrp8-ɣMSH (DTrp), that acts via ...
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... Rebekah E. Gee MD MPH FACOG, Assistant Professor, LSU ... and Medicine, has been chosen to receive a Recognition ... Leadership Award from the Association of Maternal & Child ... vision, and contributions to the health of women, children, ...
... The University of Michigan,s first human embryonic stem cell line ... registry, making the cells available for federally-funded research. It is ... University of Michigan to be placed on the registry. ... derived in October 2010 from a cluster of about 30 ...
... cues from their rivals the honeybees to learn where the ... Mary, University of London. Writing in the journal ... Biological and Chemical Sciences explain how they trained a colony ... by a different species, the honeybee ( Apis mellifera ), ...
Cached Biology News:LSUHSC's Gee honored for improving health of women, children and families 2U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Bumblebees get by with a little help from their honeybee rivals 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: